The 2023 Chinese expert consensus on Vogt-Koyanagi-Harada (VKH) syndrome provides clinical guidelines for diagnosing and treating this autoimmune disorder, which is a leading cause of blindness in China. Developed by experts from relevant medical associations, the consensus highlights the diverse clinical manifestations of VKH, the importance of early treatment for vision recovery, and specific diagnostic criteria for the Chinese population. It outlines the disease's stages, complications, and treatment options, including corticosteroids and immunosuppressants. The consensus stresses timely diagnosis and management to prevent severe complications like cataracts and glaucoma, advocating for a structured approach to optimize patient outcomes.